Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia
- 18 Downloads
Progressive multifocal leukoencephalopathy (PML) is a rapidly progressive, often fatal viral infection of the brain without a known treatment. Recently, case reports have demonstrated survival from PML with therapies that improve cell-mediated immunity, including interleukin-7 (IL-7) or the chemokine receptor type 5 (CCR5) antagonist, maraviroc (MVC). We present the first known case of a patient with PML successfully treated with both IL-7 and MVC. A 63-year-old woman presented to our center with a 6-month history of progressive left hemiparesis. Extensive laboratory testing was negative except for a severe CD4 lymphocytopenia (140/μL). Serial brain MRIs done prior to presentation revealed an enlarging, non-enhancing T2-hyperintense lesion in the right fronto-parietal white matter. PML was confirmed through detection of the JC virus by PCR in the cerebrospinal fluid and by brain biopsy, and she was started on mirtazapine and mefloquine. She continued to deteriorate and was then given a course of recombinant IL-7. Though she remained clinically stable after IL-7 treatment and serum JCV PCR decreased from 1000 copies/mL to a nadir of 238 copies/mL, a repeat MRI 3 months later showed lesion enlargement. MVC was then initiated. Now, more than 2 years after initial presentation, she remains stable and serum JCV PCR is undetectable. This case demonstrates successful treatment of PML in a patient with idiopathic CD4 lymphocytopenia and highlights the potential benefits of IL-7 and MVC in the treatment of PML. Treatment with IL-7 and MVC led to clinical stability and improvement in JC virus titers.
KeywordsProgressive multifocal leukoencephalopathy CD4 lymphocytopenia Interleukin-7 Maraviroc
The authors thank Michel Morre and RevImmune for providing recombinant IL-7.
This study was supported by an Institutional Clinical Training Award from the National Multiple Sclerosis Society.
Compliance with ethical standards
Conflict of interest
Asaff Harel has received consulting fees from Teva Pharmaceuticals.
Sam Horng reports no disclosures.
Tarah Gustafson reports no disclosures.
Anil Ramineni reports no disclosures.
Rebecca Straus Farber reports no disclosures.
Michelle Fabian has received consulting fees from Biogen pharmaceuticals.
- Ahuja SK, Kulkarni H, Catano G, Agan BK, Camargo JF, He W, O'Connell RJ, Marconi VC, Delmar J, Eron J, Clark RA, Frost S, Martin J, Ahuja SS, Deeks SG, Little S, Richman D, Hecht FM, Dolan MJ (2008) CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1 infected individuals. Nat Med 14:413–420CrossRefPubMedPubMedCentralGoogle Scholar
- Berger JR, Pall L, Lanska D, Whiteman M (1998) Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neuro-Oncol 4(1):59–68Google Scholar
- Gasnault J, De Goer de Herve MG, Michot JM et al (2014) Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy. Open Forum Infect Dis 1(2):ofu074Google Scholar
- Gheuens S, Bord E, Kesari S, Simpson DM, Gandhi RT, Clifford DB, Berger JR, Ngo L, Koralnik IJ (2011) Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 85(14):7256–7263CrossRefPubMedPubMedCentralGoogle Scholar
- Rueger MA, Miletic H, Dorries K, Wyen C, Eggers C, Deckert M, Faetkenheuer G, Jacobs AH Long-term remission in progressive multifocal leukoencephalopathy caused by idiopathic CD4+ T lymphocytopenia: a case report. Clin Infect Dis 2006; 1;42(7):e53–6Google Scholar
- Sierra-Madero J, Ellenberg S, Rassool MS et al (2014) A randomized, double-blind, placebo-controlled clinical trial of chemokine receptor 5 (CCR5) antagonist to decrease the occurrence of immune reconstitution inflammatory syndrome in HIV-infection: the CADIRIS Study. Lancet HIV 1(2):e60–e67CrossRefPubMedCentralGoogle Scholar
- Spadaro F, Cecchetti S, Purificato C, Sabbatucci M, Podo F, Ramoni C, Gessani S, Fantuzzi L (2013) Nuclear phosphoinositide-specific phospholipase C ß1 controls cytoplasmic CCL2 mRNA levels in HIV-1 gp120-stimulated primary human macrophages. PLoS One 8(3):e59705CrossRefPubMedPubMedCentralGoogle Scholar